Lung Cancer in China
“China will become the world’s leader in lung cancer patients”
– November 17, 2013 (BBC news)
Avantex’s Solution for Lung Cancer in China
For the Chinese marketplace, Avantex Biotechnologies’ proprietary Acufilic™ dual-drug delivery platform would use a combination of chemo-drugs and Chinese herb drugs. This would provide an efficacious therapeutic strategy to eradicate or provide complete suppression of the growth of advanced non-small cell lung cancer via specific elimination of EGFR-relevant mutations and drug efflux mechanism.
Lung Cancer Market to Grow to 100 Million People
At the China Lung Cancer Summit held in Beijing, experts predict that in 12 years China is likely to lead the world in lung cancer. Experts say smoking is one of the major causes of high lung cancer. Air pollution is a leading cause of lung cancer, according to a new report from the cancer agency of the World Health Organization (Source: WHO).
Lung cancer, stomach cancer and liver cancer are the three most common types of cancer in China. Lung cancer has become China’s leading cancer cause of death, with its morbidity and mortality rate increasing rapidly in the past decade since the expansion.
Experts predict that by 2025, China’s lung cancer patients will reach 100 million people, becoming the world’s number one lung cancer power.